Results 81 to 90 of about 56,993 (185)

Sevelamer worsen metabolic acidosis in hemodialysis patients

, 2006
Background: Sevelamer hydrochloride, a major phosphate binder for patients on maintenance hemodialysis (MHD) is associated with reduced serum bicarbonate concentration due to hydrochloric acid release in the gut and to the binding of short chain fatty ...
Cirillo M., Di Stazio E., Santoro D., Correale G., Ciacci C., De Santo N. G., Perna A., Iacono G., Frangiosa A., Di Meglio E., Savica V., Marino A., Stellato D., Anastasio P.   +13 more
core  

Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide

International Journal of Nephrology and Renovascular Disease, 2016
Valeria Cernaro, Domenico Santoro, Antonio Lacquaniti, Giuseppe Costantino, Luca Visconti, Antoine Buemi, Michele Buemi Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy Abstract: Chronic kidney disease-mineral bone ...
Cernaro V, Santoro D, Lacquaniti A, Costantino G, Visconti L, Buemi A, Buemi M   +6 more
doaj  

Effect of calcimimetic therapy on bone mineral disorders in patients with stage 5D chronic kidney disease

Bolʹ, Sustavy, Pozvonočnik
Background. Determination of peculiarities of the se­condary hyperparathyroidism’s course (sHPT) and its treatment in patients with chronic kidney disease (CKD) G5D is an actual problem.
Л.П. Мартинюк, Т.Л. Мальська   +1 more
doaj   +1 more source

A Sole Case of the FGF23 Gene Mutation c.202A>G (p.Thr68Ala) Associated with Multiple Severe Vascular Aneurysms and a Hyperphosphatemic Variant of Tumoral Calcinosis—A Case Report

Life
Tumoral calcinosis is an extremely rare genetic disease caused by mutations in three genes, GALNT3, FGF23, and KL, which disrupt phosphorus metabolism. The hallmark of this condition is the formation of tumors in the soft tissues around the joints. Other
Nevena Georgieva Ivanova
doaj   +1 more source

Sevelamer worsens metabolic acidosis in hemodialysis patients.

, 2006
Background: Sevelamer hydrochloride, a major phosphate binder for patients on maintenance hemodialysis (MHD) is associated with reduced serum bicarbonate concentration due to hydrochloric acid release in the gut and to the binding of short chain fatty ...
CIACCI C, ANASTASIO P, DI MEGLIO E, CORREALE G, STELLATO D, CIRILLO M., PERNA A, MARINO A, SANTORO, Domenico, DI STAZIO E, DE SANTO NG, IACONO G, FRANGIOSA A, SAVICA, Vincenzo   +13 more
core  

Management of renal osteodystrophy in children

The Turkish Journal of Pediatrics, 2005
Prevention and treatment of renal osteodystrophy (ROD) are great challenges for pediatric nephrologists. The strategies for prevention and treatment of ROD in children with chronic renal failure (CRF) should be created on an individual basis.
Velibor Tasic
doaj  

Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease

Therapeutics and Clinical Risk Management, 2020
Valeria Cernaro, Sebastiano Calimeri, Alfredo Laudani, Domenico Santoro Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Messina, ItalyCorrespondence: Valeria CernaroUnit of Nephrology and Dialysis,
Cernaro V, Calimeri S, Laudani A, Santoro D   +3 more
doaj  

Molecular Modeling Studies of the Binding Characteristics of Phosphates to Sevelamer Hydrochloride – Assessing a Novel Technique to Reduce Phosphates Contamination

, 2006
Recent advances in the use of polymeric materials for the remediation of phosphate from aqueous systems, including biological environments, have prompted the use of computational techniques to determine which methods are feasible to model such complex ...
D. Fisher, R. Parker, E. Ross, J. Edwards, A. A. Odukale, C. Batich   +5 more
core   +1 more source

Serious: Non-serious ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source

High frequency:Low frequency ratios over time.

, 2015
(A) capecitabine, (B) eldecalcitol, (C) epoetin beta pegol, (D) peginterferon alfa-2a, and (E) sevelamer hydrochloride.
Seigo Okugawa (733308), Kotonari Aoki (733302), Terumi Nakayama (733307), Takumi Kobayashi (733305), Takuya Kawamata (733303), Minami Tomita (733310), Yoshihiko Sugimura (733309), Yoichiro Takahashi (733311), Hiroshi Kuriki (733306), Shinichi Matsuda (733301), Tetsuji Kimotsuki (733304)   +10 more
core   +1 more source